Vitruvias Therapeutics thyroid tablet recall gets FDA’s highest-risk rating - here’s what to check and what patients need to know
A thyroid medicine recall has received the FDA’s highest-risk classification after testing found one lot of Thyroid Tablets, USP 30 mg could be stronger than intended. Here’s what consumers need to know about the recalled lot, potential risks, affected tablets and what the FDA advises.
The Economic Times ·